GLP-1 Weight-Loss Drugs and Rising Eating Disorders: Cure or Catalyst?

GLP-1 receptor agonists (such as semaglutide) have been hailed as one of the major biotech breakthroughs of the past decade, with their weight-loss effects drawing countless people in droves. Yet in the eyes of clinical psychologists, these drugs may play a more insidious role—as potential triggers for eating disorders. A new report notes that between 1990 and 2023, the global incidence of anorexia nervosa and bulimia nervosa soared by 71%. This figure overlaps in time with the widespread use of GLP-1 drugs, sparking discussion about the complex relationship between drug side effects and public health.

Surging Eating Disorder Incidence: A Neglected Global Trend

According to the report, from 1990 to 2023 the global incidence of anorexia nervosa and bulimia nervosa grew by 71%. This figure far exceeds the growth rates of many infectious and chronic diseases, yet it has long received insufficient attention. Eating disorders are characterized by high mortality and high relapse rates, and their treatment costs and social burden cannot be underestimated.

Traditionally, eating disorders have been viewed as psychological conditions primarily affecting young women, but recent epidemiological data show that the affected population is expanding. The reasons for the rising incidence are complex, including changes in diagnostic criteria, sociocultural pressures, and the influence of social media. The emergence of GLP-1 drugs may have added a new variable to this trend.

Anorexia nervosa and bulimia nervosa are the two most representative diagnostic categories of eating disorders. The core feature of anorexia nervosa is deliberately maintaining a body weight significantly below normal through restricted energy intake, excessive exercise, or purging behaviors; patients often have an intense fear of weight gain and a distorted perception of their own body shape, and its mortality rate ranks among the highest of all mental disorders, often resulting from arrhythmias or electrolyte imbalances caused by malnutrition. Bulimia nervosa manifests as recurrent binge eating followed by compensatory behaviors such as self-induced vomiting, laxative abuse, or excessive exercise to try to offset caloric intake; patients' weight is usually within the normal range, making it harder for others to notice. Both are frequently comorbid with depression, anxiety, and obsessive-compulsive symptoms, and have high relapse rates, requiring long-term psychological intervention combined with nutritional rehabilitation.

How GLP-1 Drugs May Exacerbate Eating Disorder Risk

GLP-1 drugs work by mimicking gut hormones to suppress appetite and slow gastric emptying, thereby achieving weight loss. While this mechanism helps obese patients improve their health, it may also be misused by people at high risk of eating disorders. Clinical psychologists warn that the "rapid sense of fullness" and "weight loss" brought by the drugs may reinforce excessive focus on body shape or become a tool for compensatory behaviors.

For example, people with eating disorder tendencies may use the drugs to suppress binge impulses without addressing the underlying psychological issues, and may instead fall into a cycle of "medication–restriction–binge." In addition, the convenience of obtaining the drugs (such as online prescriptions) lowers the barrier to use and increases the risk of off-label use.

GLP-1 receptor agonists are a class of drugs that mimic the action of the body's natural glucagon-like peptide-1 (GLP-1). GLP-1 is secreted by intestinal L cells after eating; it stimulates insulin secretion, inhibits glucagon release, and acts on appetite centers in the hypothalamus to slow gastric emptying and enhance satiety, thereby reducing food intake. Drugs such as semaglutide and liraglutide were initially used to treat type 2 diabetes and were later approved for obesity management due to their significant weight-loss effects. Notably, the satiety and weight loss produced by these drugs bear a superficial resemblance at the physiological level to certain experiences of eating disorder patients—one reason clinical psychologists worry about their misuse by high-risk groups or their reinforcement of pathological weight concerns.

Clinical Perspective: Synergy and Conflict Between Drugs and Psychotherapy

From a clinical standpoint, GLP-1 drugs are not entirely negative. For eating disorder patients with comorbid obesity, the drugs may help control weight-related health risks. But the key lies in integrating psychotherapy and behavioral intervention rather than relying on drugs alone. Currently, most clinical trials of GLP-1 drugs have not included eating disorder patients as a primary endpoint, meaning safety data in this population are limited.

Psychologists call for eating disorder screening before prescribing GLP-1 drugs and for monitoring of psychological status during treatment. At the same time, public education needs to emphasize healthy weight management rather than extreme thinness, to prevent the drugs from being misused as a "quick fix."

The primary endpoint of a randomized controlled trial refers to the core indicator pre-specified at the clinical trial design stage for evaluating drug efficacy; statistical analysis and regulatory approval are both centered on this endpoint. Registration trials of GLP-1 drugs typically use changes in glycated hemoglobin or percentage weight loss as the primary endpoint, and enrollment criteria often exclude subjects with current or past eating disorders. This means efficacy and safety data for the drugs in this high-risk subgroup are almost nonexistent, prescription decisions lack direct evidentiary support, and clinicians can only rely on case reports and expert experience to weigh risks and benefits. This evidence gap is also an important reason for calling for targeted research and the establishment of post-marketing surveillance.

Public Health and Regulatory Challenges

The popularity of GLP-1 drugs reflects society's stigmatization of obesity and excessive focus on appearance. When approving drugs, regulatory agencies typically focus on physiological indicators, while assessment of psychological and behavioral effects is relatively weak. As drug use becomes more widespread, establishing pharmacovigilance systems to capture eating disorder–related adverse events has become particularly urgent.

In addition, social media promotion of GLP-1 drugs often exaggerates benefits and downplays risks, potentially misleading vulnerable groups. Public health departments need to work with platforms to ensure accurate information and provide links to resources that help those in need.

Pharmacovigilance refers to the system for continuous monitoring, identification, and assessment of adverse events after a drug reaches the market, with the goal of detecting rare or delayed adverse reactions that could not be captured during clinical trials in larger, more real-world populations. Unlike traditional monitoring of physiological indicators, adverse events at the psychological and behavioral level (such as pathological weight concerns or the triggering or worsening of binge-purge cycles) are often difficult to detect through routine laboratory tests and require proactive capture using structured screening tools and patient-reported outcomes. Incorporating eating disorder–related symptoms into the pharmacovigilance scope of GLP-1 drugs means embedding psychological assessment into prescribing, follow-up, and data reporting—placing new demands on both existing regulatory frameworks and clinical workflows.

Future Directions: Cautious Optimism and Interdisciplinary Collaboration

The relationship between GLP-1 drugs and eating disorders still requires more research to clarify. Current evidence comes mostly from case reports and expert opinion, lacking large-scale prospective cohort studies. Future research should focus on the effects of long-term use on psychological and behavioral outcomes and develop personalized prescribing guidelines for eating disorder patients.

Interdisciplinary collaboration—including endocrinology, psychiatry, nutrition, and public health—is key to reducing risk. The drugs themselves are not the enemy, but without accompanying psychosocial support, a breakthrough technology could become a double-edged sword.

One-line Summary

GLP-1 weight-loss drugs may act as a catalyst for eating disorders, with a 71% global increase in incidence raising alarm.

Paragraph Summary

This article explores the potential link between GLP-1 receptor agonists (such as semaglutide) and the rising incidence of eating disorders. From 1990 to 2023, the global incidence of anorexia nervosa and bulimia nervosa grew by 71%, a trend that overlaps in time with the widespread use of GLP-1 drugs. Clinical psychologists warn that the drugs' appetite suppression and rapid weight loss may reinforce pathological body-image concerns or be misused by high-risk groups as compensatory tools. The article also notes that the drugs are not entirely negative and may benefit patients with comorbid obesity, but the key lies in integrating psychotherapy and behavioral intervention. Currently, most GLP-1 trials have not included eating disorder patients, so safety data are limited; the article calls for pre-prescription screening, interdisciplinary collaboration, and public health surveillance.